Sharing the details of the development, Dr Rajeev Datar of INTAS said ''With Intas Biopharmaceuticals and BPD Inc coming together, the two companies complement technical strengths of each other. Both the companies shall gain expertise from the synergies in technical areas like gene expression optimisation, medium optimisation cell culture, protein purification scale-up and analytical services, thereby expanding the scope of CRAMS activities.'' Dr Scott M Brown said ''We are pleased to become associates with Intas Biopharmaceuticals, who are leaders in area of biologics in India. Jointly, we compliment each other on technology front and we, at BPD Inc, are looking forward to jointly work with Intas Biopharmaceuticals in the area of R &D and explore new technology frontiers.'' The development will facilitate and assist Intas Biopharmaceuticals Ltd's foray in US market, especially to expand its CRAMS business. With mutual understanding and agreement, Dr Brown shall continue as President and Chief Scientific Officer of BPD Inc and Dr Datar shall be the new Chief Executive Officer of BPD Inc.